CFB
RPRX icon

Cullen/Frost Bankers’s Royalty Pharma RPRX Stock Holding History

Cullen/Frost Bankers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Hold
2,016
– – ﹤0.01% 702
2026
Q1 		$96.7K Sell
2,016
-544,334
-100% -$23.8M ﹤0.01% 677
2025
Q4 		$21.1M Buy
546,350
+89,253
+20% +$3.4M 0.23% 96
2025
Q3 		$16.1M Buy
457,097
+140,542
+44% +$5.09M 0.19% 110
2025
Q2 		$11.4M Buy
316,555
+68,592
+28% +$2.27M 0.14% 144
2025
Q1 		$7.72M Buy
247,963
+247,903
+413,172% +$7.86M 0.11% 169
2024
Q4 		$1.53K Hold
60
– – ﹤0.01% 1183
2024
Q3 		$1.7K Hold
60
– – ﹤0.01% 1133
2024
Q2 		$1.58K Buy
+60
New +$1.66K ﹤0.01% 1144

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cullen/Frost Bankers's RPRX Position: Q2 2026 in Review

Cullen/Frost Bankers held its Royalty Pharma (RPRX) position steady in Q2 2026 at 2,016 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #702.

Cullen/Frost Bankers first reported a position in RPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $21.1M in Q4 2025. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cullen/Frost Bankers held 2,016 shares of Royalty Pharma worth $113K as of Q2 2026.
  • Cullen/Frost Bankers left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #702 holding.
  • Cullen/Frost Bankers first reported a position in Royalty Pharma in Q2 2024 and has held it in 9 quarters since.
  • Cullen/Frost Bankers's Royalty Pharma position peaked at $21.1M in Q4 2025.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.